Format

Send to

Choose Destination
Mol Autism. 2018 Mar 12;9:18. doi: 10.1186/s13229-018-0203-y. eCollection 2018.

Plasma anandamide concentrations are lower in children with autism spectrum disorder.

Author information

1
1Department of Psychiatry and Behavioral Sciences, Stanford University, 401 Quarry Rd., Stanford, CA 94305 USA.
2
2Vincent Coates Foundation Mass Spectrometry Laboratory, Stanford University, 333 Campus Dr., Stanford, CA 94305 USA.
3
3Department of Comparative Medicine, Stanford University, 287 Campus Dr., Stanford, CA 94305 USA.

Abstract

Background:

Autism spectrum disorder (ASD) is a neurodevelopmental disorder characterized by restricted, stereotyped behaviors and impairments in social communication. Although the underlying biological mechanisms of ASD remain poorly understood, recent preclinical research has implicated the endogenous cannabinoid (or endocannabinoid), anandamide, as a significant neuromodulator in rodent models of ASD. Despite this promising preclinical evidence, no clinical studies to date have tested whether endocannabinoids are dysregulated in individuals with ASD. Here, we addressed this critical gap in knowledge by optimizing liquid chromatography-tandem mass spectrometry methodology to quantitatively analyze anandamide concentrations in banked blood samples collected from a cohort of children with and without ASD (N = 112).

Findings:

Anandamide concentrations significantly differentiated ASD cases (N = 59) from controls (N = 53), such that children with lower anandamide concentrations were more likely to have ASD (p = 0.041). In keeping with this notion, anandamide concentrations were also significantly lower in ASD compared to control children (p = 0.034).

Conclusions:

These findings are the first empirical human data to translate preclinical rodent findings to confirm a link between plasma anandamide concentrations in children with ASD. Although preliminary, these data suggest that impaired anandamide signaling may be involved in the pathophysiology of ASD.

KEYWORDS:

Anandamide; Autism spectrum disorder; Blood biomarker; Cannabinoid

PMID:
29564080
PMCID:
PMC5848550
DOI:
10.1186/s13229-018-0203-y
[Indexed for MEDLINE]
Free PMC Article

Conflict of interest statement

All research procedures were approved by the Stanford University Institutional Review Board prior to participant enrollment. Participants’ parents provided written consent prior to initiation of any experimental procedures, and written assent was obtained from participants when appropriate (e.g., children ≥ 7 years of age and deemed intellectually capable).Not applicable.The authors declare that they have no competing interests.Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplemental Content

Full text links

Icon for BioMed Central Icon for PubMed Central
Loading ...
Support Center